PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination

A systematic review and meta-analysis

Antonio Rossi, Vincenzo Di Noia, Anastasios Gkountakos, Ettore D'Argento, Giulia Sartori, Emanuele Vita, Sara Monteverdi, Fiorella Lombardo, Roberto Iacovelli, Luisa Carbognin, Isabella Sperduti, Michele Milella, Giampaolo Tortora, Emilio Bria, Sara Pilotto

Research output: Contribution to journalReview article

Abstract

Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; p = 0.001) and PFS (HR 0.61; p < 0.0001) compared with standard-of-care in NSCLC patients in first-line setting. Conclusion: Immunotherapy-based regimens constantly improved OS and PFS compared with chemotherapy in first-line treatment of nononcogene-addicted NSCLC.

Original languageEnglish
Pages (from-to)921-930
Number of pages10
JournalImmunotherapy
Volume11
Issue number10
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Immunotherapy
Meta-Analysis
Disease-Free Survival
Drug Therapy
Survival
Standard of Care
Histology
Therapeutics
Clinical Trials

Keywords

  • atezolizumab
  • first line
  • immunotherapy
  • meta-analysis
  • nivolumab
  • NSCLC
  • PD-1
  • PD-L1
  • pembrolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination : A systematic review and meta-analysis. / Rossi, Antonio; Noia, Vincenzo Di; Gkountakos, Anastasios; D'Argento, Ettore; Sartori, Giulia; Vita, Emanuele; Monteverdi, Sara; Lombardo, Fiorella; Iacovelli, Roberto; Carbognin, Luisa; Sperduti, Isabella; Milella, Michele; Tortora, Giampaolo; Bria, Emilio; Pilotto, Sara.

In: Immunotherapy, Vol. 11, No. 10, 01.01.2019, p. 921-930.

Research output: Contribution to journalReview article

Rossi, Antonio ; Noia, Vincenzo Di ; Gkountakos, Anastasios ; D'Argento, Ettore ; Sartori, Giulia ; Vita, Emanuele ; Monteverdi, Sara ; Lombardo, Fiorella ; Iacovelli, Roberto ; Carbognin, Luisa ; Sperduti, Isabella ; Milella, Michele ; Tortora, Giampaolo ; Bria, Emilio ; Pilotto, Sara. / PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination : A systematic review and meta-analysis. In: Immunotherapy. 2019 ; Vol. 11, No. 10. pp. 921-930.
@article{1135a97af3c04f5e897db9201df8da1c,
title = "PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis",
abstract = "Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; p = 0.001) and PFS (HR 0.61; p < 0.0001) compared with standard-of-care in NSCLC patients in first-line setting. Conclusion: Immunotherapy-based regimens constantly improved OS and PFS compared with chemotherapy in first-line treatment of nononcogene-addicted NSCLC.",
keywords = "atezolizumab, first line, immunotherapy, meta-analysis, nivolumab, NSCLC, PD-1, PD-L1, pembrolizumab",
author = "Antonio Rossi and Noia, {Vincenzo Di} and Anastasios Gkountakos and Ettore D'Argento and Giulia Sartori and Emanuele Vita and Sara Monteverdi and Fiorella Lombardo and Roberto Iacovelli and Luisa Carbognin and Isabella Sperduti and Michele Milella and Giampaolo Tortora and Emilio Bria and Sara Pilotto",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/imt-2018-0198",
language = "English",
volume = "11",
pages = "921--930",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "10",

}

TY - JOUR

T1 - PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination

T2 - A systematic review and meta-analysis

AU - Rossi, Antonio

AU - Noia, Vincenzo Di

AU - Gkountakos, Anastasios

AU - D'Argento, Ettore

AU - Sartori, Giulia

AU - Vita, Emanuele

AU - Monteverdi, Sara

AU - Lombardo, Fiorella

AU - Iacovelli, Roberto

AU - Carbognin, Luisa

AU - Sperduti, Isabella

AU - Milella, Michele

AU - Tortora, Giampaolo

AU - Bria, Emilio

AU - Pilotto, Sara

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; p = 0.001) and PFS (HR 0.61; p < 0.0001) compared with standard-of-care in NSCLC patients in first-line setting. Conclusion: Immunotherapy-based regimens constantly improved OS and PFS compared with chemotherapy in first-line treatment of nononcogene-addicted NSCLC.

AB - Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; p = 0.001) and PFS (HR 0.61; p < 0.0001) compared with standard-of-care in NSCLC patients in first-line setting. Conclusion: Immunotherapy-based regimens constantly improved OS and PFS compared with chemotherapy in first-line treatment of nononcogene-addicted NSCLC.

KW - atezolizumab

KW - first line

KW - immunotherapy

KW - meta-analysis

KW - nivolumab

KW - NSCLC

KW - PD-1

KW - PD-L1

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85067894693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067894693&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0198

DO - 10.2217/imt-2018-0198

M3 - Review article

VL - 11

SP - 921

EP - 930

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 10

ER -